Resistance to Proteasome Inhibitors in Cancer

Resistance to Proteasome Inhibitors in Cancer
Author :
Publisher :
Total Pages : 404
Release :
ISBN-10 : 3319067532
ISBN-13 : 9783319067537
Rating : 4/5 (32 Downloads)

Book Synopsis Resistance to Proteasome Inhibitors in Cancer by : Q. Ping Dou

Download or read book Resistance to Proteasome Inhibitors in Cancer written by Q. Ping Dou and published by . This book was released on 2014-10-31 with total page 404 pages. Available in PDF, EPUB and Kindle. Book excerpt:


Resistance to Proteasome Inhibitors in Cancer Related Books

Resistance to Proteasome Inhibitors in Cancer
Language: en
Pages: 404
Authors: Q. Ping Dou
Categories:
Type: BOOK - Published: 2014-10-31 - Publisher:

DOWNLOAD EBOOK

Proteasome Inhibitors in Cancer Therapy
Language: en
Pages: 319
Authors: Julian Adams
Categories: Medical
Type: BOOK - Published: 2004-05-25 - Publisher: Springer Science & Business Media

DOWNLOAD EBOOK

A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Language: en
Pages: 292
Authors:
Categories: Medical
Type: BOOK - Published: 2018-11-21 - Publisher: Academic Press

DOWNLOAD EBOOK

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strate
Proteostasis and Disease
Language: en
Pages: 350
Authors: Rosa Barrio
Categories: Science
Type: BOOK - Published: 2020-04-09 - Publisher: Springer Nature

DOWNLOAD EBOOK

This book, written by members of the European network PROTEOSTASIS, provides an up-to-date review of the research regarding protein homeostasis in health and di
Proteasome Inhibition as a Potential Anti-breast Cancer Therapy
Language: en
Pages: 71
Authors: Rahul Rajesinh Deshmukh
Categories: Breast
Type: BOOK - Published: 2015 - Publisher:

DOWNLOAD EBOOK

When verapamil, a L-type calcium channel blocker with P-glycoprotein (P-gp) and CYP3A4 inhibitory properties, is combined with MG132 or bortezomib or carfilzomi